Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H12N2O8.C4H10N2.Ca.2H |
Molecular Weight | 416.44 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[H+].[Ca++].C1CNCCN1.[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O
InChI
InChIKey=ROJMAHHOFDIQTI-UHFFFAOYSA-L
InChI=1S/C10H16N2O8.C4H10N2.Ca/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;1-2-6-4-3-5-1;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);5-6H,1-4H2;/q;;+2/p-2
Molecular Formula | H |
Molecular Weight | 1.0079 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Ca |
Molecular Weight | 40.078 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C4H10N2 |
Molecular Weight | 86.1356 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C10H12N2O8 |
Molecular Weight | 288.2109 |
Charge | -4 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfCurator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdf
Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Calcium iodide (chemical formula CaI2) is the ionic compound of calcium and iodine, used in cat food as a source of iodine This colourless deliquescent solid is a salt that is highly soluble in water. Calcium iodide properties are similar to those for related salts, such as calcium chloride. Calcium iodide is also used in photography.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
Title | Date | PubMed |
---|---|---|
A novel ubiquitously expressed alpha-latrotoxin receptor is a member of the CIRL family of G-protein-coupled receptors. | 1999 Feb 26 |
|
Aluminum is a weak agonist for the calcium-sensing receptor. | 1999 May |
|
Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. | 1999 Nov |
|
Effects of a calcium receptor activator on the cellular response to calcium in human keratinocytes. | 1999 Sep |
|
Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. | 1999 Sep |
|
Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity. | 1999 Sep 20 |
|
D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. | 2000 Dec 15 |
|
Inactivation properties of human recombinant class E calcium channels. | 2000 Feb |
|
Regulation of LPA-promoted myofibroblast contraction: role of Rho, myosin light chain kinase, and myosin light chain phosphatase. | 2000 Feb 1 |
|
Vanadate induces calcium signaling, Ca2+ release-activated Ca2+ channel activation, and gene expression in T lymphocytes and RBL-2H3 mast cells via thiol oxidation. | 2000 Jan 15 |
|
Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. | 2000 Jan 7 |
|
NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways. | 2000 Jul 17 |
|
Polyoxygenated dysidea sterols that inhibit the binding of [I125] IL-8 to the human recombinant IL-8 receptor type A. | 2000 May |
|
Dual regulation of leptin secretion: intracellular energy and calcium dependence of regulated pathway. | 2000 May |
|
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. | 2000 Nov |
|
Pharmacological blockade of ERG K(+) channels and Ca(2+) influx through store-operated channels exerts opposite effects on intracellular Ca(2+) oscillations in pituitary GH(3) cells. | 2000 Nov |
|
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats. | 2000 Nov 10 |
|
Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement. | 2000 Oct 15 |
|
High-calcium diet enhances vasorelaxation in nitric oxide-deficient hypertension. | 2000 Sep |
|
ATP induces dephosphorylation of myosin light chain in endothelial cells. | 2000 Sep |
|
Pilocarpine-induced status epilepticus causes N-methyl-D-aspartate receptor-dependent inhibition of microsomal Mg(2+)/Ca(2+) ATPase-mediated Ca(2+) uptake. | 2000 Sep |
|
Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. | 2001 Apr 27 |
|
Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells. | 2001 Aug |
|
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. | 2001 Feb 16 |
|
Functional expression and characterization of a voltage-gated CaV1.3 (alpha1D) calcium channel subunit from an insulin-secreting cell line. | 2001 Jul |
|
Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine. | 2001 Jul |
|
Analysis of the native quaternary structure of vanilloid receptor 1. | 2001 Jul 27 |
|
Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. | 2001 Jun |
|
Cloning and characterization of a novel human histamine receptor. | 2001 Mar |
|
Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. | 2001 Mar 15 |
|
Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes. | 2001 Mar 2 |
|
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. | 2001 Nov |
|
Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001 Nov 30 |
|
Microarray analysis of differential gene expression in lead-exposed astrocytes. | 2001 Oct 1 |
|
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. | 2001 Oct 26 |
|
Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism. | 2001 Sep |
|
Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore. | 2001 Sep 1 |
|
A diacylglycerol-activated Ca2+ channel in PC12 cells (an adrenal chromaffin cell line) correlates with expression of the TRP-6 (transient receptor potential) protein. | 2001 Sep 15 |
|
Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze. | 2001 Sep 7 |
|
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. | 2002 |
|
The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002 Dec |
|
CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells. | 2002 Feb |
|
Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. | 2002 Mar |
|
Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons. | 2002 Nov 4 |
|
Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension. | 2003 Jan |
|
Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial. | 2015 Aug 12 |
Sample Use Guides
oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid).
inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:04:42 UTC 2022
by
admin
on
Fri Dec 16 16:04:42 UTC 2022
|
Record UNII |
L4QEN8344Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Official Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB09869MIG
Created by
admin on Fri Dec 16 16:04:42 UTC 2022 , Edited by admin on Fri Dec 16 16:04:42 UTC 2022
|
PRIMARY | |||
|
C175844
Created by
admin on Fri Dec 16 16:04:42 UTC 2022 , Edited by admin on Fri Dec 16 16:04:42 UTC 2022
|
PRIMARY | |||
|
CHEMBL2106963
Created by
admin on Fri Dec 16 16:04:42 UTC 2022 , Edited by admin on Fri Dec 16 16:04:42 UTC 2022
|
PRIMARY | |||
|
M8846
Created by
admin on Fri Dec 16 16:04:42 UTC 2022 , Edited by admin on Fri Dec 16 16:04:42 UTC 2022
|
PRIMARY | Merck Index | ||
|
L4QEN8344Z
Created by
admin on Fri Dec 16 16:04:42 UTC 2022 , Edited by admin on Fri Dec 16 16:04:42 UTC 2022
|
PRIMARY | |||
|
122-50-9
Created by
admin on Fri Dec 16 16:04:42 UTC 2022 , Edited by admin on Fri Dec 16 16:04:42 UTC 2022
|
SUPERSEDED | |||
|
12002-30-1
Created by
admin on Fri Dec 16 16:04:42 UTC 2022 , Edited by admin on Fri Dec 16 16:04:42 UTC 2022
|
PRIMARY | |||
|
31213
Created by
admin on Fri Dec 16 16:04:42 UTC 2022 , Edited by admin on Fri Dec 16 16:04:42 UTC 2022
|
PRIMARY | |||
|
580
Created by
admin on Fri Dec 16 16:04:42 UTC 2022 , Edited by admin on Fri Dec 16 16:04:42 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY | |||
|
ACTIVE MOIETY |